Catalyst Pharmaceuticals, Inc.
CPRX
$21.12
-$0.21-0.99%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 141.42M | 141.82M | 128.70M | 122.71M | 98.51M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 141.42M | 141.82M | 128.70M | 122.71M | 98.51M |
| Cost of Revenue | 21.80M | 25.44M | 22.56M | 18.39M | 15.10M |
| Gross Profit | 119.62M | 116.38M | 106.13M | 104.32M | 83.41M |
| SG&A Expenses | 46.91M | 44.19M | 45.88M | 40.73M | 46.94M |
| Depreciation & Amortization | 9.35M | 9.34M | 9.35M | 9.34M | 9.34M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 78.05M | 78.98M | 77.79M | 68.46M | 71.38M |
| Operating Income | 63.37M | 62.84M | 50.91M | 54.25M | 27.13M |
| Income Before Tax | 71.29M | 74.18M | 57.21M | 55.79M | 29.09M |
| Income Tax Expenses | 14.55M | 18.25M | 13.32M | 14.99M | 5.81M |
| Earnings from Continuing Operations | 56.74M | 55.94M | 43.88M | 40.79M | 23.28M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 56.74M | 55.94M | 43.88M | 40.79M | 23.28M |
| EBIT | 63.37M | 62.84M | 50.91M | 54.25M | 27.13M |
| EBITDA | 72.83M | 72.30M | 60.36M | 63.68M | 36.56M |
| EPS Basic | 0.47 | 0.47 | 0.37 | 0.35 | 0.20 |
| Normalized Basic EPS | 0.35 | 0.35 | 0.29 | 0.31 | 0.16 |
| EPS Diluted | 0.45 | 0.44 | 0.35 | 0.33 | 0.19 |
| Normalized Diluted EPS | 0.34 | 0.33 | 0.28 | 0.29 | 0.15 |
| Average Basic Shares Outstanding | 121.47M | 119.89M | 118.93M | 118.18M | 116.81M |
| Average Diluted Shares Outstanding | 126.96M | 126.28M | 125.41M | 124.66M | 123.40M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |